Viral Hepatitis Market is expected to reach USD 19.73 billion by 2029

Market Analysis and Size

According to WHO data published in July 2021, 296 million individuals worldwide were living with chronic hepatitis B virus by 2019, with 1.5 million new infections each year. The highest rates of Hepatitis B infection are found in the WHO regions of the West Pacific and Africa, where 6.2 percent and 6.1 percent of people, respectively, are affected. Inflammation of the liver is referred to as hepatitis. Inflammation is the body's reaction to irritation or injury, and it usually causes swelling and pain

Data Bridge Market Research analyses that the viral hepatitis market was valued at USD 14.98 billion in 2021 and is expected to reach USD 19.73 billion by 2029, registering a CAGR of 3.50% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

View Detailed Report@ 
https://www.databridgemarketresearch.com/reports/global-viral-hepatitis-market

Viral Hepatitis Market Scope
The viral hepatitis market is segmented on the basis of disease type, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

Hepatitis A
Hepatitis B
Hepatitis C
Others
Treatment

Antiviral Drugs
Telbivudine
Entecavir
Tenofovir disoproxil
Lamivudine
Others
Vaccine
Immune Modulator Drugs
Pegylated interferon
Interferon alpha
Surgery
Others
Diagnosis

Liver Biopsy
Blood Tests
Imaging Tests
Ultrasound
MRI
CT scan
Others
Route of Administration

Oral
Parenteral
Others
End-Users

Hospitals
Specialty Clinics
Homecare
Others
Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Some of the major players operating in the viral hepatitis market are:

Pfizer Inc. (U.S.)
GlaxoSmithKline plc (U.K.)
Novartis AG (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd. (Israel)
Sanofi (France)
Boehringer Ingelheim International GmbH. (Germany)
AstraZeneca (U.K.)
Johnson & Johnson Private Limited (U.S.)
Bayer AG (Germany)
Merck & Co., Inc. (U.S.)
F. Hoffmann-La Roche Ltd. (Switzerland)
Bristol-Myers Squibb Company (U.S.)
Cadila Pharmaceuticals (India)
Eli Lilly and Company (U.S.)
LEO Pharma A/S (Denmark)
Cipla Inc. (U.S.)
Aurobindo Pharma (India)
Lupin (India)
Sumitomo Corporation (Japan)

Browse More Reports:

https://dbmrbuisness.blogspot.com/2023/09/influenza-drug-market-size-share-demand.html

https://dbmrbuisness.blogspot.com/2023/09/neglected-tropical-diseases-treatment.html

https://dbmrbuisness.blogspot.com/2023/09/global-odontogenic-sarcoma-treatment.html

https://dbmrbuisness.blogspot.com/2023/09/microbubble-contrast-media-market-by.html

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact Us:-
Data Bridge Market research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com

This release was published on openPR.